Herbert Smith Freehills

APRIL 12, 2022

He merely has a predilection for spotting opportunities and following the ones that interest him wherever they may lead. A strong interest in transactional law led to being sponsored to get his MBA, while he also began to travel internationally, often to Australia. Some people might watch a few YouTube videos or read up on a topic.

Contracts 52

Contracts Law Business Marketing 52

The IPKat

DECEMBER 11, 2023

Léon provides a brief summary of the book’s main argument below and announces a launch event on 12 January 2024 that promises to be interesting. A second, liberal view holds that patent courts should make injunctions subject to a balance of interests, to be conducted in light of all circumstances of the case. here , at 24].

Patent Law 70

Patent Law Law Patent Invention 70

The IPKat

OCTOBER 25, 2021

The Board of Appeal decision makes for an interesting read, as it explores the legal basis (or lack of) for plausibility in the case law and the EPC itself. The Opponent submitted their own data, showing that compounds falling under the scope of the claim did not have synergistic effect against P. litura and P. xylostella ).

Invention 86

Invention Publishing Patent Application Art 86

The IPKat

SEPTEMBER 5, 2023

The Judge awarded interest on the principle sum, because if Lenovo had been under a running royalty licence they would have made four payments annually, each one shortly after the end of each quarter ([21]). He awarded interest at the rate agreed between the parties in the draft licence i.e. 4% compounded quarterly.

Technology 67

Technology Publishing Reporting Marketing 67

LexBlog IP

OCTOBER 27, 2021

The first study covering these topics was released on March 13, 2018, and the second on July 18, 2019. Orange Book patents cover only drug compound, formulation, and method claims. Another interesting statistic with regards to Orange Book and biologics patent trends is the low settlement rate. See 21 C.F.R. § § 314.53(b).

Patent 52

Patent Settlement Litigation Reporting 52

Kluwer Copyright Blog

APRIL 22, 2022

Readers interested in the topic, should also note another important study on copyright and AI conducted in parallel and just released by the team of Alain Strowel, Sari Depreeuw, Luc Desaunettes-Barbero et al., 1] (On the topic of AI outputs and derivative works, see here.). Example workflow diagram by artist duo Hyper Music.

Music 67

Music Copyright Derivative Work Ownership 67

LexBlog IP

JANUARY 18, 2022

With apologies to those who prefer a classic menu, I’ll be approaching these topics in coming weeks in a mezze fashion, with several items arranged to whet your appetite and enrich your knowledge. This one is for trademark fans as well as cooks and has an interesting backstory. Olive Oil and State Pride.

Law 52

Law Trademark Branding Brands 52

Technology & Marketing Law Blog

JUNE 27, 2022

Third, this bill reaches topics well beyond children’s privacy. Instead, the bill repeatedly implicates general consumer protection concerns and, most troublingly, content moderation topics. ” The scope of this taskforce likely exceeds privacy topics. We don’t do “A-for-Effort” laws in the U.S.,

Privacy 137

Privacy Designs Design Business 137

Velocity of Content

JANUARY 26, 2022

In RightFind, reseachers and investigators can analyze previously published studies and create reviews of articles pertaining to a topic, such as a specific disease, chemical compound, or ingredient. Interested in seeing real examples of how R&D teams use RightFind and our copyright licensing solutions? Regulatory.

Marketing 98

Marketing Marketing Licensing Publishing 98

LexBlog IP

DECEMBER 31, 2022

A machine learning model can be trained on pharmaceutical, bio, and other life sciences and/or healthcare data to aid researchers with early-stage drug discovery, including the development of new drug compounds and the development of discovery technologies to assist with next-generation sequencing. Radiotherapy and Radiology.

Intellectual Property 52

Intellectual Property IP Technology Privacy 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Companies are also continuing to invest in clinical trials of biosimilars of new compounds, such as Amgen, which is running Phase 3 clinical trials of ABP 938 (a biosimilar to Eylea ® (aflibercept)), ABP 654 (a biosimilar to Stelara ® (ustekinumab)), and ABP 959 (a biosimilar to Soliris ® (eculizumab)).

Litigation 52

Litigation Settlement Patent Marketing 52